PinnyPeptide

Bronchogen vs Pancragen

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Bronchogen

Bioregulators

Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue.

Peptide B

Pancragen

Bioregulators

Khavinson short peptide bioregulator targeting pancreatic tissue and glucose metabolism.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists longer via gene-expression modulation

FDA status

Not FDA approved.

Typical vial

20 mg

Typical dose

1,000-5,000 mcg

Half-life

Short (minutes); biological effect persists via gene-expression modulation

FDA status

Not FDA approved.

Bronchogen effects

  • Reported restoration of bronchial epithelial function
  • Improvement in pulmonary function tests (Russian observational data)
  • Reduction in COPD/bronchitis exacerbation frequency
  • Improved dyspnea and exercise tolerance
  • Anti-inflammatory effects in bronchial tissue

Pancragen effects

  • Reported support of residual β-cell function
  • Improvements in fasting glucose and HbA1c (Russian observational)
  • Support of exocrine pancreatic function
  • Improvement in digestion in pancreatic insufficiency
  • Modulation of pancreatic gene expression

Bronchogen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Occasional allergic reactions (rare)
  • Limited Western safety validation

Pancragen side effects

  • Generally well-tolerated in Russian clinical use
  • Mild injection-site reactions
  • Limited Western safety validation
  • Should not substitute for proven diabetes therapies

Bronchogen dosing ranges

Bronchial function support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Pancragen dosing ranges

Pancreatic support

1-5 mg · Once daily (SubQ) or sublingual · 10-20 day cycles, repeated 2-3 times per year

Full Bronchogen guide → Full Pancragen guide →

Bronchogen vs Pancragen — common questions

What is the difference between Bronchogen and Pancragen?

Bronchogen: Khavinson short peptide bioregulator targeting bronchial epithelium and lung tissue. Typical dose 1,000-5,000 mcg. Pancragen: Khavinson short peptide bioregulator targeting pancreatic tissue and glucose metabolism. Typical dose 1,000-5,000 mcg. Both fall under the Bioregulators category.

Can you stack Bronchogen and Pancragen?

Stacking Bronchogen with Pancragen is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Bronchogen or Pancragen?

Bronchogen is typically dosed: Once daily (SubQ) or sublingual for Bronchial function support. Pancragen is typically dosed: Once daily (SubQ) or sublingual for Pancreatic support.

Are Bronchogen and Pancragen FDA approved?

Bronchogen: Not FDA approved. Pancragen: Not FDA approved.

Related peptide comparisons

bronchogen vs cardiogenbronchogen vs cartalaxbronchogen vs cortagenbronchogen vs crystagenbronchogen vs ovagencardiogen vs pancragen

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free